Inhibition of SOX9 in IGH-BCL2⁺ DLBCL cells impairs cell survival and proliferation. Immunoblot (A) and CFSE proliferation (B) assays of SOX9⁻ Karpas-422 and DB cells. (C) Hemocytometer counts of the number of SOX9⁻ Karpas-422 and DB cells. (D) SOX9⁻ Karpas-422 and DB cells were exposed to BrdU for 4 hours before flow cytometry analysis. Quantitation of the percentage distribution of cell cycle phases was determined by gating of live cells in the G₁ (light gray bar), S (dark gray bar), or G₂ (white bar) phases. (E) Immunoblot assay of expression of Bcl-xL, Mcl-1, Bcl-2, Bad, and Bax. β-Actin was included as the control for equal loading. (C-D) Data represent the mean ± SD of technical triplicates. ****P < .005. CFSE, carboxyfluorescein diacetate succinimidyl ester.